Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710097 · ClinicalTrials.gov registry record · Phase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
A Phase 1 study of Cannabis and Alcohol Effect, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02710097 is a Phase 1 study of Cannabis and Alcohol Effect that is active but no longer recruiting, run by Yale University. The registered enrollment target is 40 participants, below the 109-participant average among 24 other Cannabis trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02710097, a Phase 1 study of Cannabis and Alcohol Effect, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Active inhaled cannabis
- DRUG Active Oral Ethanol
Study Locations (1)
Connecticut
- Biological Studies Unit, VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710097
The ClinicalTrials.gov registry entry for NCT02710097 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 24 other Cannabis trials with a reported enrollment target (63% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cannabis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02710097 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02710097 about?
NCT02710097 is a clinical study titled "Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II". The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
What is the current status of trial NCT02710097?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2025-12.
What conditions does trial NCT02710097 study?
This clinical trial studies the following conditions: Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs.
What interventions are being tested in trial NCT02710097?
The interventions under investigation include: Placebo (DRUG), Active inhaled cannabis (DRUG), Active Oral Ethanol (DRUG).
Who is sponsoring clinical trial NCT02710097?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710097 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
RECRUITING · Phase 1
-
Cannabinoids, Learning, and Memory
ACTIVE NOT RECRUITING · Phase 1
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.